Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.35 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | EBP | Q15125 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31545933 | 0.77 | MDM2 (0.36) | POLBMAPT | |
| SCHEMBL31546208 | 0.74 | GLA (0.34) | POLBKMT2A | |
| SCHEMBL10699635 | 0.74 | POLB (0.41) | POLBDAOTP53TSHRSIGMAR1 | |
| SCHEMBL25258805 | 0.73 | TSHR (0.43) | TP53TSHRSIGMAR1EBPMEN1 | |
| SCHEMBL31546106 | 0.71 | TP53 (0.39) | POLBDAOTP53TSHRSIGMAR1 | |
| SCHEMBL31546186 | 0.69 | CYP1A2 (0.42) | KMT2A | |
| SCHEMBL12919128 | 0.68 | L3MBTL1 (0.31) | MEN1KMT2AMAPT | |
| SCHEMBL26475122 | 0.66 | CRBN (0.66) | POLBKMT2A | |
| SCHEMBL12919014 | 0.66 | HSD11B1 (0.34) | TSHRMEN1KMT2AMAPTKCNH2 | |
| SCHEMBL31546123 | 0.65 | RAB9A (0.41) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250090440-A1 | NOVEL CYCLIC ACETAL COMPOUNDS WITH ALDEHYDE OR KETONE FUNCTIONALITIES AND USES THEREOF | Structure Holdings, LLC (US) | 2025-03-20 | — | — | US | claimed |
| US-20250090440-A1 | NOVEL CYCLIC ACETAL COMPOUNDS WITH ALDEHYDE OR KETONE FUNCTIONALITIES AND USES THEREOF | Structure Holdings, LLC (US) | 2025-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250090440-A1 | NOVEL CYCLIC ACETAL COMPOUNDS WITH ALDEHYDE OR KETONE FUNCTIONALITIES AND USES THEREOF | OR51E2, TAS2R5, TRPA1 | POLB 4192/4885DAO 467/4885TP53 2992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.